CYCLACEL PHARMA (NQ: CYCC)
3.230 USD  UNCHANGED
Official Closing Price  /  Updated: 8:10 PM EDT, Apr 15, 2014  /  Add to My Watchlist      
(CYCC) Community Analysis from
April 16, 2014
(Benzinga, 10/7/10)
Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases, announced...(read more)
(Benzinga, 10/5/10)
Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) announced today that it has agreed to sell approximately $15.2 million of units to several institutional investors including the Special Situations Funds. The investors...(read more)
(Stock Blog Hub, 3/29/10)
Cyclacel Pharmaceuticals, Inc.’s (CYCC) fourth quarter fiscal 2009 net loss per share came in at 18 cents, wider than the Zacks Consensus Estimate by a penny. The year-ago loss...(read more)
Cyclacel Pharmaceuticals (CYCC) Company Overview

Based in Short Hills, New Jersey, Cyclacel Pharmaceuticals, Inc. (CYCC) is a clinical-stage company dedicated to the discovery, development, and commercialization of small molecule cell cycle inhibitors for the treatment of cancers and other serious disorders. The company's expertise lies in the area of Cell Cycle Inhibition which is a mechanism-targeted approach for the treatment of cancer and other serious proliferative diseases. Cyclacel aims to develop novel, cell-cycle-based mechanism-targeted cancer therapies that will stop the growth of cancer cells and will limit the damage caused to normal cells. The company's lead development candidate is a cyclin dependent kinase (CDK) inhibitor, CYC202 (seliciclib), which is in phase II trials for the treatment of non-small cell lung cancer (NSCLC). The second candidate, CYC682 (sapacitabine), is a nucleoside analog which is undergoing a randomized phase II trial in patients with advanced cutaneous T-cell lymphoma (CTCL) and another phase II trial in elderly patients with AML. The company is also developing CYC116, an Aurora kinase inhibitor, for the treatment of cancer, and initiated a phase I trial in June 2007, following submission of an investigational new drug (IND) application in December, 2006. The company has an additional eight early stage programs, which target cell cycle mechanisms for the treatment of cancer, type II diabetes, inflammatory kidney diseases, and viral infections (HIV/ AIDS). The following table summarizes the pipeline programs for the company.

Targeted Drug Pipeline

(Read more at Wikinvest )

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here